CONTRIBUTORS

Cerebrovascular Disease p. 252-256 April 2020, Vol.26, No.2 doi: 10.1212/01.CON.0000660084.99789.d7
CONTRIBUTORS
BROWSE ARTICLES

Natalia S. Rost, MD, MPH, FAAN, FAHA Guest Editor

Chief of the Stroke Division, Department of Neurology, Massachusetts General Hospital; Professor of Neurology, Harvard Medical School, Boston, Massachusetts

Relationship Disclosure: Dr Rost serves as an assistant editor for Stroke and has received personal compensation for serving on the scientific advisory boards for Omniox and Sanofi Genzyme and as a consultant for Abbvie Inc. Dr Rost has received research/grant support as a principal investigator for the National Institute of Neurological Disorders and Stroke (R01 NS082285, R01 NS086905, and U19 NS115388) and publishing royalties as a contributor to UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Rost reports no disclosure.

Andrei V. Alexandrov, MD

Professor and Chair of Neurology, University of Tennessee Health Science Center at Memphis, Memphis, Tennessee

Relationship Disclosure: Dr Alexandrov has received personal compensation for speaking engagements for Genentech, Inc, research/grant support from the Assisi Foundation of Memphis, Inc, and royalties from John Wiley & Sons, Inc and has given expert testimony.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Alexandrov reports no disclosure.

Anne W. Alexandrov, PhD, AGACNP-BC, ANVP-BC, FAAN

Professor of Nursing, Professor of Neurology, University of Tennessee Health Science Center at Memphis, Memphis, Tennessee; Professor, Partner, Health Outcomes Institute, LLC, Fountain Hills, Arizona

Relationship Disclosure: Dr Anne Alexandrov has received personal compensation for speaking engagements for Genentech, Inc and research/grant support from the National Institutes of Health (1R01NR017850-01) and serves as the President-Elect of the Association of Neurovascular Clinicians, the organization offering the advanced neurovascular practitioner certification examination.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Alexandrov reports no disclosure.

Cheryl Bushnell, MD, MHS

Professor, Vice Chair of Research, Stroke Section Chief, Wake Forest Baptist Health, Winston Salem, North Carolina

Relationship Disclosure: Dr Bushnell has received research/grant support from the Agency for Healthcare Research and Quality (1R01HS025723-01), the National Institutes of Health/National Institute of Neurological Diseases and Stroke (1U24NS107235-01), and the Patient-Centered Outcomes Research Institute (PCS-11403-14531) and publishing royalties from Henry Stewart Talks Ltd and Oxford University Press.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Bushnell reports no disclosure.

Hanne Christensen, MD, PhD, DMSci

Professor, Bispebjerg Hospital and Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Relationship Disclosure: Dr Christensen has served on the advisory board of Boehringer Ingelheim International GmbH and has received personal compensation for speaking engagements from Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, and Daiichi-Sankyo. Dr Christensen has received research/grant support from the Lundbeck Foundation, Toyota Fonden Denmark, the TrygFonden, and the Velux Foundations and publishing royalties from Gyldendal Forlag.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Christensen reports no disclosure.

Steven C. Cramer, MD, MMSc, FAHA, FAAN

Professor, University of California, Los Angeles; Medical Director of Research, California Rehabilitation Institute, Los Angeles, California

Relationship Disclosure: Dr Cramer has served as a consultant for AbbVie Inc; Biogen; Constant Therapeutics, LLC; Fujifilm Toyama Chemical Co, Ltd; MicroTransponder Inc; NeuroLutions; Regenera Pharma; SanBio Co, Ltd; Stemedica Cell Technologies, Inc; and TRCare, Inc. Dr Cramer has received grant or research support from SanBio Co, Ltd and National Institutes of Health (grant R01 NR015591) and royalties from Cambridge University Press and the University of California.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Cramer reports no disclosure.

Mark Etherton, MD, PhD

Associate Director, Acute Stroke Services, Massachusetts General Hospital; Instructor, Harvard Medical School, Boston, Massachusetts

Relationship Disclosure: Dr Etherton has received a research grant from the American Heart Association (17CPOST33680102).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Etherton reports no disclosure.

Karen Furie, MD

Chief of Neurology, Rhode Island Hospital, The Miriam Hospital, and Bradley Hospital; Chair, Department of Neurology, The Warren Alpert Medical School, Brown University, Providence, Rhode Island

Relationship Disclosure: Dr Furie has received personal compensation for serving on an advisory committee for the American Heart Association and as a deputy editor for the Journal of Neurology, Neurosurgery & Psychiatry, and Stroke, and has received research/grant support from the National Institutes of Health, StrokeNet, and UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Furie reports no disclosure.

Hooman Kamel, MD

Chief, Division of Neurocritical Care, Weill Cornell Medicine, New York, New York

Relationship Disclosure: Dr Kamel has served on an end point adjudication committee for Boehringer Ingelheim International GmbH, on a steering committee for a stroke/atrial fibrillation trial for Medtronic (uncompensated), as a deputy editor for JAMA Neurology and on an advisory board for Roivant Sciences Ltd. Dr Kamel receives research/grant support from the Michael Goldberg Stroke Research Fund; the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (R01HL144541); the NIH/National Institute of Neurological Disorders and Stroke (U01NS095869, U01NS106513, R01NS097443); and as co–principal investigator of the NIH-funded ARCADIA trial, which receives in-kind study drugs from Bristol-Myers Squibb–Pfizer Alliance and in-kind study assays from Roche Diagnostics, North America.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Kamel discusses the class of anticoagulant drugs, specifically, directacting oral anticoagulant drugs, for various indications related to cryptogenic stroke.

Joseph S. Kass, MD, JD, FAAN

Associate Dean, Office of Student Affairs; Professor of Neurology, Psychiatry, and Medical Ethics; Director, Alzheimer’s Disease and Memory Disorders Center, Baylor College of Medicine; Chief of Neurology, Ben Taub General Hospital, Houston, Texas

Relationship Disclosure: Dr Kass serves as associate editor of medicolegal issues for Continuum, as an associate editor for Continuum Audio, as a neurology section editor of Ferri’s Clinical Advisor for Elsevier, and as co-editor of Neurology Secrets, Sixth Edition. Dr Kass has received personal compensation for CME lectures from Pri-Med LLC and as a principal investigator for clinical trials for Alzheimer disease from Biogen, Eisai Co Ltd, Eli Lily and Company, National Institutes of Health, Novartis AG, and Roche Diagnostics.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Kass reports no disclosure.

Anthony S. Kim, MD, MAS

Associate Professor of Neurology, Erich Fried Endowed Professor in Vascular Neuroscience, Department of Neurology, Weill Institute for Neurosciences; Medical Director, UCSF Stroke Center, University of California San Francisco, San Francisco, California

Relationship Disclosure: Dr Kim has received personal compensation for serving as an associate editor for NEJM: Journal Watch Neurology and research/grant support from the National Center for Advancing Translational Sciences, the National Institute of Neurological Disorders and Stroke, the Patient-Centered Outcomes Research Institute, and SanBio Company, Ltd.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Kim discusses the unlabeled/investigational use of cilostazol and ticagrelor for stroke prevention and direct oral anticoagulants for embolic stroke of undetermined source.

Bijoy K. Menon, MD, DM, MSc, FRCPC

Associate Professor, Departments of Clinical Neurosciences, Radiology, and Community Health Sciences, Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Alberta, Canada

Relationship Disclosure: Dr Menon has received research/grant support from Alberta Innovates, the Canadian Institutes of Health Research (363959), and the Heart and Stroke Foundation of Canada. Dr Menon has held stock in Circle Neurovascular Imaging Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Menon reports no disclosure.

Raul Nogueira, MD

Associate Professor, Professor of Neurology, Neurosurgery and Radiology, Emory University School of Medicine, Director, Neuroendovascular Service, Marcus Stroke & Neuroscience Center, Grady Memorial Hospital, Atlanta, GA

Relationship Disclosure: Dr Nogueira has received personal compensation for serving as a principal investigator for Cerenovus/Neuravi Ltd, Imperative Care Inc, and Phenox, Inc; on the physician advisory board for Anaconda Biomed SL, Genentech, Inc, and Prolong Pharmaceuticals; and on a steering committee for Biogen. Dr Nogueira has received grants/research support from Koninklijke Philips NV, the Ministry of Health (Brazil), and Sensome and has held stock options in Astrocyte Pharmaceuticals Inc, Brainomix, Ceretrieve Ltd, Corindus, Inc, Vesalio, LLC, and Viz.ai, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Nogueira report no disclosure.

Jukka Putaala, MD, PhD, MSc

Chief of Stroke Unit, Helsinki University Hospital, Associate Professor, University of Helsinki, Helsinki, Finland

Relationship Disclosure: Dr Putaala has served on the scientific advisory board for Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb/Pfizer Inc, and Portola Pharmaceuticals, Inc; is an editorial board member of the European Stroke Journal; and is a visiting editor for Terve Media. Dr Putaala has received compensation for lectures for Abbott, Bayer AG, Boehringer Ingelheim, and Bristol-Myers Squibb/Pfizer Inc and for research collaboration for BCB Medical Ltd, Bittium, Nokia Technologies, and Vital Signum. Dr Putaala has received research funding from the Academy of Finland, Business Finland, Hospital District of Helsinki and Uusimaa, Pfizer Inc, and St. Jude Medical, Inc, and owns stock in Vital Signum.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Putaala reports no disclosure.

Alejandro Rabinstein, MD, FAAN

Professor of Neurology, Mayo Clinic, Rochester, Minnesota

Relationship Disclosure: Dr Rabinstein has served as an associate editor for Neurocritical Care and on the editorial board of Continuum: Lifelong Learning in Neurology. Dr Rabinstein has received royalties from Elsevier, Oxford University Press, and UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Rabinstein discusses the unlabeled/investigational use of alteplase for the treatment of acute ischemic stroke beyond 3 hours and tenecteplase for the treatment of acute ischemic stroke.

Rachel V. Rose, JD, MBA

Attorney, Rachel V. Rose Attorney at Law, PLLC; Affiliated Faculty, Baylor College of Medicine, Houston, Texas

Relationship Disclosure: Ms Rose serves on the editorial board of BC Advantage and receives book royalties from the American Bar Association.

Unlabeled Use of Products/Investigational Use Disclosure: Ms Rose reports no disclosure.

Ynte M. Ruigrok, MD, PhD

Assistant Professor, University Medical Center Utrecht, Utrecht, Netherlands

Relationship Disclosure: Dr Ruigrok reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Ruigrok reports no disclosure.

Gisele Silva MD, MPH, PhD

Associate Professor, Universidade Federal de São Paulo; Neurologist and Clinical Trialist, Hospital Israelita Albert Einstein, São Paulo, Brazil

Relationship Disclosure: Dr Silva has received compensation for serving on advisory boards for Bard Pharmaceuticals Ltd and Boehringer Ingelheim International GmbH and for serving on a speaker’s bureau for Bayer AG, Boehringer Ingelheim International GmbH, and Pfizer Inc and has received research support from the Ministry of Health (Brazil) (02216643) and Servier.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Silva reports no disclosures.

Michael F. Waters, MD, PhD, FAAN, FAHA

Professor of Neurology, Barrow Neurological Institute, University of Arizona College of Medicine; Professor of Neurology, Creighton School of Medicine; Director, Neurovascular Division and Stroke Program, Barrow Neurological Institute, Phoenix, Arizona

Relationship Disclosure: Dr Waters has received grant support from the Barrow Neurological Foundation and has provided medical opinion during the discovery phase of a lawsuit.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Waters reports no disclosure.

Self-Assessment and CME Test Writers

Douglas J. Gelb, MD, PhD, FAAN

Professor of Neurology, University of Michigan, Ann Arbor, Michigan

Relationship Disclosure: Dr Gelb receives royalties from MedLink, Oxford University Press, and UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Gelb reports no disclosure.

Allyson R. Zazulia, MD

Professor of Neurology and Radiology, Associate Dean for Continuing Medical Education, Washington University, St. Louis, Missouri

Relationship Disclosure: Dr Zazulia reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Zazulia reports no disclosure.

© 2020 American Academy of Neurology.